lansoprazole has been researched along with Esophagitis, Reflux in 107 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the clinical efficacy of the second-generation H2RA lafutidine with that of lansoprazole in Japanese patients with mild gastroesophageal reflux disease (GERD)." | 9.22 | Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease. ( Haruma, K; Inoue, M; Kawano, S; Kinoshita, Y; Komatsu, H; Komazawa, Y; Kushiyama, Y; Manabe, N; Mukai, S; Nagata, S; Okada, H; Okanobu, H; Onogawa, S; Takenaka, R; Tanaka, S; Todo, H; Yoshinaga, F, 2016) |
| "GERD patients with dyspepsia were enrolled and treated with lansoprazole 15 or 30 mg once daily for 4 weeks." | 9.19 | Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia. ( Haruma, K; Kinoshita, Y; Miwa, H; Miyata, K; Sanada, K, 2014) |
| "To compare the efficacy of esomeprazole and lansoprazole at their standard dosages in suppressing oesophageal acid exposure in complicated gastro-oesophageal reflux disease." | 9.12 | Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. ( De Micheli, E; Frazzoni, M; Manno, M; Savarino, V, 2006) |
| "To assess the efficacy and safety of lansoprazole in the treatment of adolescents with symptomatic, endoscopically proven, non-erosive gastroesophageal reflux disease and erosive esophagitis." | 9.11 | Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. ( Fiedorek, S; Gold, BD; Gremse, D; Huang, B; Lee, C; Stolle, J; Tolia, V, 2005) |
| ": Effective intra-oesophageal acid suppression can be accomplished more reliably with lansoprazole than with pantoprazole in patients with complicated and atypical gastro-oesophageal reflux disease." | 9.10 | Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2003) |
| " The pharmacological activity of AFE and pure scopoletin at the same equivalent dose present in AFE was investigated in rat on gastro-esophageal inflammatory models (acid reflux esophagitis, acute gastritis induced by ethanol and serotonin, and chronic gastric ulcer induced by acetic acid); gastric biochemical parameters and gastrointestinal motility." | 7.77 | Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats. ( Kasiwong, S; Mahattanadul, S; Nima, S; Phdoongsombut, N; Ratanasuwon, P; Ridtitid, W, 2011) |
| "A marked increase in body gastritis was observed in H pylori infected individuals during long term treatment with the proton pump inhibitor lansoprazole." | 7.69 | Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. ( Berstad, A; Berstad, AE; Brandtzaeg, P; Hatlebakk, JG; Maartmann-Moe, H, 1997) |
| "Lansoprazole was superior to famotidine in reducing the thickness of esophageal wall." | 6.69 | Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux. ( Aibe, T; Eto, S; Fujisaki, T; Iida, T; Matsuoka, H; Mine, S; Morimoto, I; Tabata, T; Tanaka, Y; Yamada, S, 2000) |
| "Normally, hiccups are treated without intervention." | 5.39 | The adjuvant use of lansoprazole, clonazepam and dimenhydrinate for treating intractable hiccups in a patient with gastritis and reflux esophagitis complicated with myocardial infarction: a case report. ( Kamnasaran, D; Maximov, G, 2013) |
| "To compare the clinical efficacy of the second-generation H2RA lafutidine with that of lansoprazole in Japanese patients with mild gastroesophageal reflux disease (GERD)." | 5.22 | Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease. ( Haruma, K; Inoue, M; Kawano, S; Kinoshita, Y; Komatsu, H; Komazawa, Y; Kushiyama, Y; Manabe, N; Mukai, S; Nagata, S; Okada, H; Okanobu, H; Onogawa, S; Takenaka, R; Tanaka, S; Todo, H; Yoshinaga, F, 2016) |
| "GERD patients with dyspepsia were enrolled and treated with lansoprazole 15 or 30 mg once daily for 4 weeks." | 5.19 | Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia. ( Haruma, K; Kinoshita, Y; Miwa, H; Miyata, K; Sanada, K, 2014) |
| "The purpose of this 24-week treatment study was to evaluate the effects of three treatment strategies after 8 weeks of lansoprazole therapy for gastroesophageal reflux disease in children." | 5.15 | The effects of three alternative treatment strategies after 8 weeks of proton pump inhibitor therapy for GERD in children. ( Choe, YH; Kim, MJ; Lee, JH; Lee, JS, 2011) |
| "To compare the efficacy of esomeprazole and lansoprazole at their standard dosages in suppressing oesophageal acid exposure in complicated gastro-oesophageal reflux disease." | 5.12 | Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. ( De Micheli, E; Frazzoni, M; Manno, M; Savarino, V, 2006) |
| "The aim was to compare esomeprazole with lansoprazole for the maintenance of healed erosive esophagitis and resolution of gastroesophageal reflux disease-related symptoms in a United States population." | 5.12 | Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. ( Devault, KR; Johanson, JF; Johnson, DA; Liu, S; Sostek, MB, 2006) |
| "To assess the efficacy and safety of lansoprazole in the treatment of adolescents with symptomatic, endoscopically proven, non-erosive gastroesophageal reflux disease and erosive esophagitis." | 5.11 | Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. ( Fiedorek, S; Gold, BD; Gremse, D; Huang, B; Lee, C; Stolle, J; Tolia, V, 2005) |
| "With 8 weeks' treatment, esomeprazole 40 mg once daily heals moderate to severe EE faster and in more patients, and resolves heartburn in more patients after 4 weeks of treatment, than lansoprazole 30 mg once daily." | 5.11 | Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. ( Fennerty, MB; Hwang, C; Johanson, JF; Sostek, M, 2005) |
| "Heartburn, regurgitation and dysphagia were hardly found in any group at 8 weeks after 15 mg or 30 mg lansoprazole treatment." | 5.11 | Management of symptoms in step-down therapy of gastroesophageal reflux disease. ( Iida, T; Kishikawa, H; Mine, S; Tabata, T; Tanaka, Y, 2005) |
| " This study compared esomeprazole with lansoprazole for the healing of erosive esophagitis and resolution of heartburn." | 5.10 | Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. ( Castell, DO; Johnson, DA; Kahrilas, PJ; Levine, JG; Richter, JE; Skammer, W; Vakil, NB; Zuckerman, S, 2002) |
| ": Effective intra-oesophageal acid suppression can be accomplished more reliably with lansoprazole than with pantoprazole in patients with complicated and atypical gastro-oesophageal reflux disease." | 5.10 | Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2003) |
| "Rabeprazole may be more effective than omeprazole and lansoprazole for the rapid relief of heartburn symptoms in patients with reflux esophagitis." | 5.10 | Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. ( Adachi, K; Fujishiro, H; Hamamoto, N; Hashimoto, T; Hattori, S; Hirakawa, K; Kaji, T; Katsube, T; Kinoshita, Y; Komazawa, Y; Mihara, T; Miyake, T; Niigaki, M; Ono, M; Shizuku, T; Suetsugu, H; Taniura, H; Yagi, J; Yamamoto, S, 2003) |
| " However, lansoprazole appears to have a more rapid onset of reduction of acid gastro-oesophageal reflux than omeprazole over a 48 h period." | 5.08 | Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis. ( Burnham, WR; Kamm, MA; Newton, M, 1998) |
| "The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief." | 4.95 | Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. ( Li, MJ; Li, Q; Liu, LQ; Sun, M, 2017) |
| "The proton pump inhibitors (PPIs) lansoprazole (LPZ) and omeprazole (OPZ) have been widely used for more than 20 years in the treatment of acid-related diseases such as gastro-duodenal ulcers and reflux esophagitis." | 4.89 | Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity. ( Satoh, H, 2013) |
| " A daily dose of 30 mg lansoprazole reduced epigastric pain faster than omeprazole 20 mg daily in patients with peptic ulcer disease but healing rates at 4 and 8 weeks were similar with both agents at these dosages." | 4.81 | Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses. ( Gremse, DA, 2001) |
| " The dose of lansoprazole needed to heal the esophagitis was not significantly associated with the risk for clinical relapse (hazard ratio [HR] 1." | 3.80 | High rate of clinical and endoscopic relapse after healing of erosive peptic esophagitis in children and adolescents. ( Brito, HS; Kawakami, E; Machado, RS; Ogata, SK; Yamamoto, E, 2014) |
| "Lansoprazole is an effective acid pump inhibitor acting at the final enzymatic step of the acid secretory pathway of the parietal cell, decreasing gastric acid secretion regardless of the primary stimulus." | 3.77 | Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. ( Barradell, LB; Faulds, D; McTavish, D, 1992) |
| " The pharmacological activity of AFE and pure scopoletin at the same equivalent dose present in AFE was investigated in rat on gastro-esophageal inflammatory models (acid reflux esophagitis, acute gastritis induced by ethanol and serotonin, and chronic gastric ulcer induced by acetic acid); gastric biochemical parameters and gastrointestinal motility." | 3.77 | Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats. ( Kasiwong, S; Mahattanadul, S; Nima, S; Phdoongsombut, N; Ratanasuwon, P; Ridtitid, W, 2011) |
| "To determine if patients with gastro-oesophageal reflux disease (GERD), who were previously managed on lansoprazole 30 mg twice daily, could be maintained on rabeprazole 20 mg once daily." | 3.74 | Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center. ( Coté, GA; Ferreira, MR; Howden, CW; Rozenberg-Ben-Dror, K, 2007) |
| " The first compares primary coronary angioplasty with streptokinase in the treatment of acute myocardial infarction, in the second trial, lansoprazole is compared with omeprazole in the treatment of reflux oesophagitis." | 3.70 | Sample size calculation in economic evaluations. ( Al, MJ; Michel, BC; Rutten, FF; van Hout, BA, 1998) |
| "A marked increase in body gastritis was observed in H pylori infected individuals during long term treatment with the proton pump inhibitor lansoprazole." | 3.69 | Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. ( Berstad, A; Berstad, AE; Brandtzaeg, P; Hatlebakk, JG; Maartmann-Moe, H, 1997) |
| " Safety endpoints included treatment-emergent adverse events (TEAEs)." | 2.94 | Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. ( Chen, M; Chong, CF; Chun, HJ; Dai, N; Fei, G; Funao, N; Goh, KL; Sheu, BS; Xiao, Y; Zhang, S; Zhou, W, 2020) |
| "Rates of EE recurrence during the 24-wk maintenance period were 16." | 2.87 | Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. ( Ashida, K; Hiramatsu, N; Hori, T; Iwakiri, K; Kudou, K; Nishimura, A; Sakurai, Y; Umegaki, E, 2018) |
| "A PPI test improved symptoms in the GERD group irrespective of age, but this improvement was not observed in non-GERD group." | 2.77 | Clinically distinct characteristics in patients younger than 40 years old with non-cardiac chest pain. ( Hong, SN; Kim, JH; Kim, SI; Ko, SY; Lee, JH; Lee, KJ; Lee, SY; Park, HS; Shim, CS; Sung, IK, 2012) |
| "Lansoprazole was administered for 8 weeks and HRQOL assessed using the SF-8 and a newly developed questionnaire for RE-specific HRQOL (RESQ) at baseline and after 4 and 8 weeks of treatment." | 2.73 | The demographic characteristics and health-related quality of life in a large cohort of reflux esophagitis patients in Japan with reference to the effect of lansoprazole: the REQUEST study. ( Ashida, K; Hongo, M; Kinoshita, Y; Miwa, H, 2008) |
| "and lansoprazole 15 mg o." | 2.71 | Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. ( Bayerdörffer, E; Bigard, MA; De Freitas, D; Devière, J; Eklund, S; Fried, M; Kristjánsdóttir, S; Larkö, A; Lauritsen, K; Morris, J; Mózsik, G; Murray, F; Orive, V; Rodrigo, L; Savarino, V; Schneider, H; Vetvik, K, 2003) |
| " This study was designed to investigate the dosing patterns of patients on on-demand treatment and to compare lansoprazole with omeprazole in this regard." | 2.70 | On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. ( Grove, O; Johnsson, F; Moum, B; Simren, M; Thoring, M; Vilien, M, 2002) |
| " No drug related severe adverse event was reported." | 2.70 | [Complementary observational study of the efficacy, tolerance and safety of lansoprazole 15 mg as maintenance therapy of reflux esophagitis in daily medical practice in Belgium (record RU49749/R002]. ( Azerad, MA; Fassotte, C; Penson, J; Puttemans, M, 2001) |
| "For the long term maintenance treatment of reflux esophagitis several strategies have been proposed with the aim of reducing the daily dosage or the frequency of drug administration." | 2.70 | Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. ( Baldi, F; Cappiello, R; Ghersi, S; Morselli-Labate, AM, 2002) |
| "Lansoprazole was safe and effective for the treatment of reflux esophagitis in this trial." | 2.69 | A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. ( Dorsch, E; Earnest, DL; Greski-Rose, PA; Jennings, DE; Jones, J, 1998) |
| "Lansoprazole or ranitidine was given to 133 patients for 4-8 weeks in a double-blind, randomized, parallel group, multicentre trial." | 2.69 | Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group. ( Jansen, JB; Van Oene, JC, 1999) |
| "Lansoprazole was superior to famotidine in reducing the thickness of esophageal wall." | 2.69 | Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux. ( Aibe, T; Eto, S; Fujisaki, T; Iida, T; Matsuoka, H; Mine, S; Morimoto, I; Tabata, T; Tanaka, Y; Yamada, S, 2000) |
| "Lansoprazole is a H+." | 2.68 | Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. ( Bardhan, KD; Brocklebank, D; Hawkey, CJ; Long, RG; Morgan, AG; Moules, IK; Wormsley, KG, 1995) |
| "Lansoprazole is a new proton pump inhibitor which produces prolonged decrease of gastric acidity." | 2.68 | A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. ( Avner, D; Greski-Rose, PA; Jennings, DE; Jhala, N; Robinson, M; Sahba, B, 1995) |
| "Lansoprazole was significantly superior to placebo in maintaining healing and preventing recurrence of symptoms." | 2.68 | Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. ( Avner, D; Haber, M; Lanza, F; Robinson, M, 1996) |
| "Lansoprazole was superior to ranitidine in providing relief of upper abdominal burning and daytime heartburn (p < 0." | 2.68 | Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. ( Campbell, DR; Castell, D; Fleischmann, R; Kogut, DG; Lehman, GA; McFarland, M; Richter, J; Robinson, M; Sabesin, S; Sontag, SJ, 1997) |
| "Lansoprazole was significantly more effective than ranitidine for relief of heartburn and reduction of antacid tablet use." | 2.67 | Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group. ( Feldman, M; Fisher, RS; Greski-Rose, PA; Harford, WV; Jennings, DE; Murray, SB; Sampliner, RE, 1993) |
| "Lansoprazole was found to be an effective and safe alternative to omeprazole in short-term treatment of moderate reflux oesophagitis." | 2.67 | Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial. ( Berstad, A; Carling, L; Ekström, P; Halvorsen, L; Hatlebakk, JG; Hovdenak, N; Stallemo, A; Svedberg, LE; Trondstad, R; Unge, P, 1993) |
| "Dexlansoprazole DDR has the potential to outperform traditional PPIs based on the metabolism and novel pharmacokinetics." | 2.45 | Dexlansoprazole MR. ( Aslam, N; Wright, R, 2009) |
| "The treatment of Barrett's esophagus is controversial." | 2.43 | [The clinical strategy for the Barrett's esophagus]. ( Goto, H; Kitabatake, S; Niwa, Y, 2005) |
| " Multicentre randomised controlled studies are needed to better define the efficacy profile, the optimal dosage with respect to the different indications and the safety profile for chronic therapy of proton pump inhibitors in children." | 2.42 | Proton pump inhibitors in children: a review. ( Gerarduzzi, T; Marchetti, F; Ventura, A, 2003) |
| " The bioavailability of lansoprazole is 85%; that of omeprazole is 54%." | 2.39 | Lansoprazole and omeprazole in the treatment of acid peptic disorders. ( Blum, RA, 1996) |
| "Both are first-choice drugs for the treatment of reflux esophagitis in China." | 1.72 | Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China. ( Bao, Y; Cai, L; Gu, Y; Li, X; Yang, T; Zhang, Z, 2022) |
| "Normally, hiccups are treated without intervention." | 1.39 | The adjuvant use of lansoprazole, clonazepam and dimenhydrinate for treating intractable hiccups in a patient with gastritis and reflux esophagitis complicated with myocardial infarction: a case report. ( Kamnasaran, D; Maximov, G, 2013) |
| "Nonwhite patients with GERD had less severe baseline erosive oesophagitis, but were less likely than white patients to have erosive oesophagitis healing after 8-week PPI therapy." | 1.37 | Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors. ( Illueca, M; Johnson, DA; Monyak, JT; Sharma, P, 2011) |
| "It was shown that gastroesophageal reflux disease was one of the possible causes of eosinophilia." | 1.34 | [A case of gastroesophageal reflux disease with marked eosinophilia]. ( Inoue, T; Inui, Y; Katata, T; Kizu, T; Kohro, T; Matsumoto, Y; Miyoshi, R; Nishikawa, M; Watanabe, C; Yasunaga, Y, 2007) |
| "In conclusion, GERD in children manifests differently than that in adults and symptoms vary with patient age." | 1.33 | Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients. ( Amer, F; Chiu, YL; Gupta, SK; Hassall, E; Heyman, MB, 2006) |
| "The other two approaches prevent more recurrences: waiting to initiate maintenance therapy until symptoms recur once requires an additional $73 for each recurrence prevented whereas maintenance PPI from the outset requires an additional $819 for each recurrence prevented." | 1.30 | Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. ( Harris, RA; Kuppermann, M; Richter, JE, 1997) |
| "Within both the patient and volunteers groups, there were no significant differences between day 1 and day 7 in any of the pharmacokinetic parameters including maximum concentration (Cmax), area under the concentration-time curve (AUC), and terminal half-life of elimination (t(1/2))." | 1.30 | Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. ( Barclay, ML; Begg, EJ; Ketelbey, JW; Peters, WA; Robson, RA, 1999) |
| "If patients experience a symptomatic recurrence on the H2RA strategies, they then receive PPI maintenance." | 1.30 | Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. ( Harris, RA; Kuppermann, M; Richter, JE, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 40 (37.38) | 18.2507 |
| 2000's | 49 (45.79) | 29.6817 |
| 2010's | 15 (14.02) | 24.3611 |
| 2020's | 3 (2.80) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Z | 1 |
| Bao, Y | 1 |
| Cai, L | 1 |
| Gu, Y | 1 |
| Yang, T | 1 |
| Li, X | 1 |
| Xiao, Y | 1 |
| Zhang, S | 1 |
| Dai, N | 1 |
| Fei, G | 1 |
| Goh, KL | 1 |
| Chun, HJ | 1 |
| Sheu, BS | 1 |
| Chong, CF | 1 |
| Funao, N | 1 |
| Zhou, W | 1 |
| Chen, M | 1 |
| O'Hara, J | 1 |
| Stocken, DD | 1 |
| Watson, GC | 1 |
| Fouweather, T | 1 |
| McGlashan, J | 1 |
| MacKenzie, K | 1 |
| Carding, P | 1 |
| Karagama, Y | 1 |
| Wood, R | 1 |
| Wilson, JA | 1 |
| Li, MJ | 1 |
| Li, Q | 1 |
| Sun, M | 1 |
| Liu, LQ | 1 |
| Kajihara, Y | 1 |
| Ashida, K | 4 |
| Iwakiri, K | 1 |
| Hiramatsu, N | 1 |
| Sakurai, Y | 1 |
| Hori, T | 1 |
| Kudou, K | 1 |
| Nishimura, A | 1 |
| Umegaki, E | 1 |
| Moriwaki, M | 1 |
| Iwamoto, K | 1 |
| Ishii, K | 1 |
| Takahagi, S | 1 |
| Hide, M | 1 |
| Kinoshita, Y | 7 |
| Miwa, H | 4 |
| Sanada, K | 1 |
| Miyata, K | 1 |
| Haruma, K | 2 |
| Maximov, G | 1 |
| Kamnasaran, D | 1 |
| Yamamoto, E | 1 |
| Brito, HS | 1 |
| Ogata, SK | 1 |
| Machado, RS | 1 |
| Kawakami, E | 1 |
| Labenz, J | 1 |
| Armstrong, D | 1 |
| Leodolter, A | 1 |
| Baldycheva, I | 1 |
| Takenaka, R | 1 |
| Okada, H | 1 |
| Kawano, S | 1 |
| Komazawa, Y | 2 |
| Yoshinaga, F | 1 |
| Nagata, S | 1 |
| Inoue, M | 1 |
| Komatsu, H | 1 |
| Onogawa, S | 1 |
| Kushiyama, Y | 1 |
| Mukai, S | 1 |
| Todo, H | 1 |
| Okanobu, H | 1 |
| Manabe, N | 1 |
| Tanaka, S | 1 |
| Fock, KM | 1 |
| Ang, TL | 1 |
| Hongo, M | 3 |
| Kovacs, TO | 1 |
| Freston, JW | 1 |
| Haber, MM | 2 |
| Hunt, B | 1 |
| Atkinson, S | 1 |
| Peura, DA | 1 |
| Aslam, N | 1 |
| Wright, R | 1 |
| Wyrwich, KW | 1 |
| Mody, R | 1 |
| Larsen, LM | 1 |
| Lee, M | 1 |
| Harnam, N | 1 |
| Revicki, DA | 1 |
| Lee, JH | 2 |
| Kim, MJ | 1 |
| Lee, JS | 1 |
| Choe, YH | 1 |
| Mahattanadul, S | 1 |
| Ridtitid, W | 1 |
| Nima, S | 1 |
| Phdoongsombut, N | 1 |
| Ratanasuwon, P | 1 |
| Kasiwong, S | 1 |
| Sharma, P | 1 |
| Johnson, DA | 3 |
| Monyak, JT | 1 |
| Illueca, M | 1 |
| Ko, SY | 1 |
| Kim, SI | 1 |
| Kim, JH | 1 |
| Lee, KJ | 1 |
| Hong, SN | 1 |
| Lee, SY | 1 |
| Sung, IK | 1 |
| Park, HS | 1 |
| Shim, CS | 1 |
| Satoh, H | 2 |
| Schilling, D | 1 |
| Adamek, HE | 1 |
| Riemann, JF | 1 |
| Johnsson, F | 1 |
| Moum, B | 1 |
| Vilien, M | 1 |
| Grove, O | 1 |
| Simren, M | 1 |
| Thoring, M | 1 |
| Mitsunaga, A | 1 |
| Matsumoto, R | 1 |
| Hoshino, Y | 1 |
| Nakamura, S | 1 |
| Murata, Y | 1 |
| Oi, I | 1 |
| Hayashi, N | 1 |
| Frazzoni, M | 2 |
| De Micheli, E | 2 |
| Grisendi, A | 1 |
| Savarino, V | 3 |
| Vakil, N | 1 |
| Lauritsen, K | 1 |
| Devière, J | 1 |
| Bigard, MA | 2 |
| Bayerdörffer, E | 1 |
| Mózsik, G | 1 |
| Murray, F | 1 |
| Kristjánsdóttir, S | 1 |
| Vetvik, K | 1 |
| De Freitas, D | 1 |
| Orive, V | 1 |
| Rodrigo, L | 1 |
| Fried, M | 1 |
| Morris, J | 1 |
| Schneider, H | 1 |
| Eklund, S | 1 |
| Larkö, A | 1 |
| Kawamura, M | 1 |
| Ohara, S | 1 |
| Koike, T | 1 |
| Iijima, K | 1 |
| Suzuki, J | 1 |
| Kayaba, S | 1 |
| Noguchi, K | 1 |
| Hamada, S | 1 |
| Noguchi, M | 1 |
| Shimosegawa, T | 1 |
| Raghunath, AS | 1 |
| Green, JR | 1 |
| Edwards, SJ | 2 |
| Marchetti, F | 1 |
| Gerarduzzi, T | 1 |
| Ventura, A | 1 |
| Adachi, K | 2 |
| Hashimoto, T | 1 |
| Hamamoto, N | 1 |
| Hirakawa, K | 1 |
| Niigaki, M | 1 |
| Miyake, T | 1 |
| Taniura, H | 1 |
| Ono, M | 1 |
| Kaji, T | 1 |
| Suetsugu, H | 1 |
| Yagi, J | 1 |
| Mihara, T | 1 |
| Katsube, T | 1 |
| Fujishiro, H | 1 |
| Shizuku, T | 1 |
| Hattori, S | 1 |
| Yamamoto, S | 1 |
| Fennerty, MB | 1 |
| Johanson, JF | 2 |
| Hwang, C | 1 |
| Sostek, M | 1 |
| Fiedorek, S | 1 |
| Tolia, V | 1 |
| Gold, BD | 1 |
| Huang, B | 1 |
| Stolle, J | 1 |
| Lee, C | 1 |
| Gremse, D | 1 |
| Dohmen, W | 2 |
| Fuchs, W | 3 |
| Ott, EA | 1 |
| Mazzoleni, LE | 1 |
| Edelweiss, MI | 1 |
| Sander, GB | 1 |
| Wortmann, AC | 1 |
| Theil, AL | 1 |
| Somm, G | 1 |
| Cartell, A | 1 |
| Rivero, LF | 1 |
| Uchôa, DM | 1 |
| Francesconi, CF | 1 |
| Prolla, JC | 1 |
| Scarpignato, C | 1 |
| Xu, JY | 1 |
| Xie, XP | 1 |
| Hou, XH | 1 |
| Kitabatake, S | 1 |
| Niwa, Y | 1 |
| Goto, H | 1 |
| Mine, S | 2 |
| Iida, T | 2 |
| Tabata, T | 2 |
| Kishikawa, H | 1 |
| Tanaka, Y | 2 |
| Manno, M | 1 |
| Habu, Y | 2 |
| Maeda, K | 1 |
| Kusuda, T | 1 |
| Yoshino, T | 1 |
| Shio, S | 1 |
| Yamazaki, M | 1 |
| Hayakumo, T | 1 |
| Hayashi, K | 1 |
| Watanabe, Y | 1 |
| Kawai, K | 2 |
| Devault, KR | 1 |
| Liu, S | 1 |
| Sostek, MB | 1 |
| Gupta, SK | 1 |
| Hassall, E | 1 |
| Chiu, YL | 1 |
| Amer, F | 1 |
| Heyman, MB | 1 |
| Lind, T | 1 |
| Lundell, L | 1 |
| Coté, GA | 1 |
| Ferreira, MR | 1 |
| Rozenberg-Ben-Dror, K | 1 |
| Howden, CW | 1 |
| Miyoshi, R | 1 |
| Yasunaga, Y | 1 |
| Kizu, T | 1 |
| Inoue, T | 1 |
| Watanabe, C | 1 |
| Matsumoto, Y | 1 |
| Katata, T | 1 |
| Inui, Y | 1 |
| Kohro, T | 1 |
| Nishikawa, M | 1 |
| Dítĕ, P | 1 |
| Prásek, J | 1 |
| Bardhan, KD | 1 |
| Hawkey, CJ | 1 |
| Long, RG | 2 |
| Morgan, AG | 1 |
| Wormsley, KG | 1 |
| Moules, IK | 1 |
| Brocklebank, D | 1 |
| Ponce, J | 1 |
| Nos, P | 1 |
| Umeda, N | 1 |
| Miki, K | 1 |
| Hoshino, E | 1 |
| Robinson, M | 5 |
| Sahba, B | 1 |
| Avner, D | 2 |
| Jhala, N | 1 |
| Greski-Rose, PA | 3 |
| Jennings, DE | 3 |
| Campbell, DR | 3 |
| Sontag, S | 1 |
| Sabesin, SM | 1 |
| Feldman, M | 1 |
| Harford, WV | 1 |
| Fisher, RS | 1 |
| Sampliner, RE | 1 |
| Murray, SB | 1 |
| Arnold, R | 1 |
| Seifert, E | 2 |
| Hatlebakk, JG | 4 |
| Berstad, A | 4 |
| Carling, L | 2 |
| Svedberg, LE | 1 |
| Unge, P | 1 |
| Ekström, P | 2 |
| Halvorsen, L | 1 |
| Stallemo, A | 1 |
| Hovdenak, N | 1 |
| Trondstad, R | 1 |
| Lanza, F | 1 |
| Haber, M | 2 |
| Blum, RA | 1 |
| Castell, DO | 3 |
| Richter, JE | 4 |
| Sontag, SJ | 4 |
| Kogut, DG | 2 |
| Fleischmann, R | 2 |
| Richter, J | 2 |
| Gough, AL | 1 |
| Cooper, BT | 1 |
| Fosters, CS | 1 |
| Garrett, AD | 1 |
| Langworthy, CH | 1 |
| Mathias, SD | 1 |
| Elkin, EP | 1 |
| Matosian, ML | 1 |
| Mulder, CJ | 2 |
| Dekker, W | 1 |
| Gerretsen, M | 1 |
| Schnell, TG | 1 |
| Chejfec, G | 1 |
| Kurucar, C | 1 |
| Karpf, J | 1 |
| Levine, G | 1 |
| McFarland, M | 1 |
| Sabesin, S | 1 |
| Lehman, GA | 1 |
| Castell, D | 1 |
| Harris, RA | 2 |
| Kuppermann, M | 2 |
| Vcev, A | 1 |
| Stimac, D | 1 |
| Vceva, A | 1 |
| Rubinić, M | 1 |
| Ivandić, A | 1 |
| Ivanis, N | 1 |
| Horvat, D | 1 |
| Volarić, M | 1 |
| Karner, I | 1 |
| Chiba, N | 1 |
| Berstad, AE | 1 |
| Maartmann-Moe, H | 1 |
| Brandtzaeg, P | 1 |
| Earnest, DL | 1 |
| Dorsch, E | 1 |
| Jones, J | 1 |
| King, VJ | 1 |
| Al, MJ | 1 |
| van Hout, BA | 1 |
| Michel, BC | 1 |
| Rutten, FF | 1 |
| Axelsson, CK | 1 |
| Forssell, H | 1 |
| Stubberöd, A | 1 |
| Kraglund, K | 1 |
| Bonnevie, O | 1 |
| Newton, M | 1 |
| Burnham, WR | 1 |
| Kamm, MA | 1 |
| Müller, P | 1 |
| Peifer-Weiss, A | 1 |
| Simon, B | 1 |
| Barclay, ML | 1 |
| Begg, EJ | 1 |
| Robson, RA | 1 |
| Peters, WA | 1 |
| Ketelbey, JW | 1 |
| Omura, N | 1 |
| Kashiwagi, H | 1 |
| Chen, G | 1 |
| Suzuki, Y | 1 |
| Yano, F | 1 |
| Aoki, T | 1 |
| Jansen, JB | 1 |
| Van Oene, JC | 1 |
| Fujisaki, T | 1 |
| Matsuoka, H | 1 |
| Yamada, S | 1 |
| Morimoto, I | 1 |
| Eto, S | 1 |
| Aibe, T | 1 |
| Endo, M | 1 |
| Sugihara, K | 1 |
| Oyasu, K | 1 |
| Wakamatsu, T | 1 |
| Sumitomo, Y | 1 |
| Kiyota, K | 1 |
| Inokuchi, H | 1 |
| Stolte, M | 1 |
| Vieth, M | 1 |
| Schmitz, JM | 1 |
| Alexandridis, T | 1 |
| Ose, C | 1 |
| Hirche, H | 1 |
| Jöckel, KH | 1 |
| Küppers, B | 1 |
| Warth, L | 1 |
| Rammler, B | 1 |
| Bardou, M | 1 |
| Dupas, JL | 1 |
| Houcke, P | 1 |
| Samoyeau, R | 1 |
| Dean, BB | 1 |
| Siddique, RM | 1 |
| Yamashita, BD | 1 |
| Bhattacharjya, AS | 1 |
| Ofman, JJ | 1 |
| Yokohama, S | 1 |
| Ishizeki, K | 1 |
| Tamori, K | 1 |
| Inaba, M | 1 |
| Tani, M | 1 |
| Makino, I | 1 |
| Cohen, JS | 1 |
| Penson, J | 1 |
| Azerad, MA | 1 |
| Puttemans, M | 1 |
| Fassotte, C | 1 |
| Gremse, DA | 1 |
| Kahrilas, PJ | 1 |
| Vakil, NB | 1 |
| Zuckerman, S | 1 |
| Skammer, W | 1 |
| Levine, JG | 1 |
| Westerveld, BD | 1 |
| Smit, JM | 1 |
| Oudkerk Pool, M | 1 |
| Otten, MH | 1 |
| Tan, TG | 1 |
| van Milligen de Wit, AW | 1 |
| de Groot, GH | 1 |
| Baldi, F | 1 |
| Morselli-Labate, AM | 1 |
| Cappiello, R | 1 |
| Ghersi, S | 1 |
| Sekiguchi, T | 1 |
| Horikoshi, T | 1 |
| Nishioka, T | 1 |
| Kusano, M | 1 |
| Barradell, LB | 1 |
| Faulds, D | 1 |
| McTavish, D | 1 |
| Inatomi, N | 1 |
| Nagaya, H | 1 |
| Takami, K | 1 |
| Shino, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Double-Dummy Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Compared to Lansoprazole 30 mg in the Treatment of Subjects With Erosive Esophagitis[NCT02388724] | Phase 3 | 481 participants (Actual) | Interventional | 2015-03-24 | Completed | ||
| A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR)[NCT02755753] | Phase 4 | 143 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once-daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis[NCT00251719] | Phase 3 | 2,054 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis[NCT00255164] | Phase 3 | 451 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis.[NCT00321737] | Phase 3 | 445 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once- Daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis[NCT00251693] | Phase 3 | 2,038 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Pilot Study to Evaluate Safety and Effectiveness of Lanreotide in the Treatment of Patients With Small Bowel Motility Disorders (SBMD): a Prospective, Non-randomized, Single-center Study of 20 Participants[NCT03012594] | Phase 2 | 12 participants (Actual) | Interventional | 2017-05-11 | Completed | ||
| Dyspeptic Symptoms Evolution After Eradication of Helicobacter Pylori in Patients With Different Endoscopic Findings: a Randomized Double-blind Placebo-controlled Clinical Trial With 12 Months of Follow-up[NCT00404534] | Phase 3 | 407 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Phase I, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of H008 (Carenoprazan Hydrochloride Tablets) in Healthy Volunteers[NCT05050188] | Phase 1 | 24 participants (Actual) | Interventional | 2021-06-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. (NCT02388724)
Timeframe: On or after the start of study drug (Day 1) to 14 days after the last dose of study medication (up to 10 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Vonoprazan 20 mg | 93 |
| Lansoprazole 30 mg | 86 |
Endoscopic healing is defined as participants endoscopically diagnosed as Los Angeles classification grade O during the treatment phase. Grade O indicates there are no mucosal breaks in the mucosa. (NCT02388724)
Timeframe: 8 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Vonoprazan 20 mg | 92.4 |
| Lansoprazole 30 mg | 91.3 |
The change between the serum gastrin values collected at Weeks 2, 4, and 8 relative to baseline. (NCT02388724)
Timeframe: Baseline and Weeks 2, 4, and 8
| Intervention | pmol/L (Mean) | |||
|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | |
| Lansoprazole 30 mg | 3.65 | 8.33 | 6.81 | 4.71 |
| Vonoprazan 20 mg | 2.77 | 31.45 | 29.68 | 36.53 |
The change between the serum pepsinogen I values collected at Weeks 2, 4, and 8 relative to baseline. (NCT02388724)
Timeframe: Baseline and Weeks 2, 4, and 8
| Intervention | micrograms per liter (ug/L) (Mean) | |||
|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | |
| Lansoprazole 30 mg | 99.8 | 129.3 | 118.3 | 117.8 |
| Vonoprazan 20 mg | 97.6 | 456.5 | 421.8 | 326.8 |
The change between the serum pepsinogen II values collected at Weeks 2, 4, and 8 relative to baseline. (NCT02388724)
Timeframe: Baseline and Weeks 2, 4, and 8
| Intervention | ug/L (Mean) | |||
|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | |
| Lansoprazole 30 mg | 7.8 | 8.8 | 7.2 | 8.0 |
| Vonoprazan 20 mg | 7.5 | 44.9 | 40.7 | 31.0 |
Clinical Laboratory Safety tests included Chemistry, Hematology and Urinalysis. Number of participants with any markedly abnormal values in laboratory tests collected throughout study is reported. ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyl transferase, CPK = creatine phosphokinase, BUN = blood urea nitrogen, LLN = lower limit of normal or lower reference limit, ULN = upper limit of normal or upper reference limit, g/L = grams per liter, U/L = units per liter, mmol/L = millimoles per liter, pmol/L = picomoles per liter. (NCT02388724)
Timeframe: From Day 1 to 14 days after the last dose of study medication (up to 10 weeks)
| Intervention | Participants (Count of Participants) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin (<0.8 x LLN g/L) | Neutrophils (<0.5 x LLN %) | Eosinophils (>2 x ULN %) | Lymphocytes (>1.5 x ULN %) | ALT (>3 x ULN U/L) | AST (>3 x ULN U/L) | GGT (>3 x ULN U/L) | CPK (>5 x ULN U/L) | Total Protein (>1.2 x ULN g/L) | BUN (>10.7 mmol/L) | Total Cholesterol (>7.72 mmol/L) | Triglycerides (>2.5 x ULN mmol/L) | Vitamin B12 (<92 pmol/L) | |
| Lansoprazole 30 mg | 1 | 2 | 0 | 2 | 2 | 1 | 3 | 2 | 1 | 1 | 2 | 3 | 1 |
| Vonoprazan 20 mg | 0 | 0 | 1 | 0 | 0 | 0 | 4 | 1 | 0 | 1 | 3 | 6 | 0 |
Number of participants with any markedly abnormal 12-lead ECG findings is reported. bpm = beats per minute, msec = milliseconds, CHG= change from baseline. (NCT02388724)
Timeframe: From Day 1 to 14 days after the last dose of study medication (up to 10 weeks)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Heart Rate (<50 bpm) | QT Interval (≥460 msec) | QTcF Interval (≥500, or ≥450 with CHG ≥30 msec) | |
| Lansoprazole 30 mg | 7 | 10 | 5 |
| Vonoprazan 20 mg | 6 | 7 | 3 |
Number of participants with any markedly abnormal vital signs measurements is reported. Vital signs included body temperature (oral, tympanic, or infra-axillary measurement), sitting blood pressure (5 minutes), and pulse. °C = degrees Celsius, mmHg = millimeters of mercury, bpm = beats per minute. (NCT02388724)
Timeframe: From Day 1 to 14 days after the last dose of study medication (up to 10 weeks)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Body Temperature (<35.6 °C) | Body Temperature (>37.7 °C) | Systolic Blood Pressure (<85 mmHg) | Diastolic Blood Pressure (>110 mmHg) | Pulse (<50 bpm) | |
| Lansoprazole 30 mg | 3 | 0 | 1 | 0 | 2 |
| Vonoprazan 20 mg | 10 | 2 | 1 | 1 | 2 |
Endoscopic healing is defined as participants endoscopically diagnosed as Los Angeles classification grade O during the treatment phase. Grade O indicates there are no mucosal breaks in the mucosa. (NCT02388724)
Timeframe: Week 2 and Week 4
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 2 Weeks | 4 Weeks | |
| Lansoprazole 30 mg | 67.8 | 83.5 |
| Vonoprazan 20 mg | 75.0 | 85.3 |
Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy. Change in LA Classification grades C or D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: Week 8
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 77.8 |
| Dexlansoprazole MR 90 mg QD | 86.3 |
| Lansoprazole 30 mg QD | 78.9 |
Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades C or D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 87.6 |
| Dexlansoprazole MR 90 mg QD | 93.3 |
| Lansoprazole 30 mg QD | 87.7 |
Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 4 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 69.7 |
| Dexlansoprazole MR 90 mg QD | 70.6 |
| Lansoprazole 30 mg QD | 65.4 |
Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 4 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 80.1 |
| Dexlansoprazole MR 90 mg QD | 80.4 |
| Lansoprazole 30 mg QD | 77.0 |
Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A (greater than or equal to 1 mucosal break and less than 5 mm). If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 86.9 |
| Dexlansoprazole MR 90 mg QD | 89.4 |
| Lansoprazole 30 mg QD | 84.6 |
Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 93.1 |
| Dexlansoprazole MR 90 mg QD | 94.9 |
| Lansoprazole 30 mg QD | 91.5 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Days (Mean) |
|---|---|
| Placebo QD | 29.5 |
| Dexlansoprazole MR 60 mg QD | 79.7 |
| Dexlansoprazole MR 90 mg QD | 79.2 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was reported. (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Days (Median) |
|---|---|
| Placebo QD | 19.2 |
| Dexlansoprazole MR 60 mg QD | 95.8 |
| Dexlansoprazole MR 90 mg QD | 94.4 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Days (Mean) |
|---|---|
| Placebo QD | 48.3 |
| Dexlansoprazole MR 60 mg QD | 87.1 |
| Dexlansoprazole MR 90 mg QD | 85.4 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Days (Median) |
|---|---|
| Placebo QD | 50.0 |
| Dexlansoprazole MR 60 mg QD | 98.3 |
| Dexlansoprazole MR 90 mg QD | 97.1 |
Crude rates analyzed maintenance of healed EE from baseline of this study and considered prematurely discontinued subjects as relapsed. (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Subjects (Number) |
|---|---|
| Placebo QD | 14.3 |
| Dexlansoprazole MR 60 mg QD | 66.4 |
| Dexlansoprazole MR 90 mg QD | 64.5 |
Percentage of subjects who maintained complete healing of erosive esophagitis as assessed by endoscopy. In the life table method, subjects without post-baseline endoscopy were included as censored; subjects who did not have a recurrence of EE and did not complete the study were also considered censored. (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Subjects (Number) |
|---|---|
| Placebo QD | 25.7 |
| Dexlansoprazole MR 60 mg QD | 86.6 |
| Dexlansoprazole MR 90 mg QD | 82.1 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Days (Mean) |
|---|---|
| Placebo QD | 36.0 |
| Dexlansoprazole MR 30 mg QD | 83.3 |
| Dexlansoprazole MR 60 mg QD | 78.4 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was reported. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Days (Median) |
|---|---|
| Placebo QD | 28.6 |
| Dexlansoprazole MR 30 mg QD | 96.1 |
| Dexlansoprazole MR 60 mg QD | 90.9 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Days (Mean) |
|---|---|
| Placebo QD | 57.7 |
| Dexlansoprazole MR 30 mg QD | 89.3 |
| Dexlansoprazole MR 60 mg QD | 86.0 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Days (Median) |
|---|---|
| Placebo QD | 71.7 |
| Dexlansoprazole MR 30 mg QD | 98.9 |
| Dexlansoprazole MR 60 mg QD | 96.2 |
Crude rates analyzed maintenance of healed EE from baseline of this study and considered prematurely discontinued subjects as relapsed. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Subjects (Number) |
|---|---|
| Placebo QD | 14.3 |
| Dexlansoprazole MR 30 mg QD | 66.4 |
| Dexlansoprazole MR 60 mg QD | 66.4 |
Percentage of subjects who maintained complete healing of erosive esophagitis as assessed by endoscopy. In the life table method, subjects without post-baseline endoscopy were included as censored; subjects who did not have a recurrence of EE and did not complete the study were also considered censored. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Subjects (Number) |
|---|---|
| Placebo QD | 27.2 |
| Dexlansoprazole MR 30 mg QD | 74.9 |
| Dexlansoprazole MR 60 mg QD | 82.5 |
Percentage of subjects with baseline EE grade C or D combined who have complete healing of erosive esophagitis as assessed by endoscopy for Change in LA Esophagitis Classification Grades C and D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 79.7 |
| Dexlansoprazole MR 90 mg QD | 74.1 |
| Lansoprazole 30 mg QD | 65.0 |
Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy for Change in LA Esophagitis Classification Grades C and D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 88.9 |
| Dexlansoprazole MR 90 mg QD | 83.8 |
| Lansoprazole 30 mg QD | 74.5 |
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A (greater than or equal to 1 mucosal break and less than 5 mm). If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 Weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 85.3 |
| Dexlansoprazole MR 90 mg QD | 85.8 |
| Lansoprazole 30 mg QD | 79.0 |
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 4 Weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 66.2 |
| Dexlansoprazole MR 90 mg QD | 68.8 |
| Lansoprazole 30 mg QD | 64.8 |
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 4 Weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 77.0 |
| Dexlansoprazole MR 90 mg QD | 78.8 |
| Lansoprazole 30 mg QD | 76.5 |
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 92.3 |
| Dexlansoprazole MR 90 mg QD | 92.2 |
| Lansoprazole 30 mg QD | 86.1 |
"Improvement in symptoms assessed by improvement in Patient Assessment of Gastrointestinal Disorders Symptom Severity Index(PAGI-SYM) scores. If the PAGI-Sym scores were decreased by at least 0.7 points at 3 months when compared to baseline/pre treatment, then it will be considered that Lanreotide has significantly improved the symptom severity. Higher values represent worse symptoms.~The participant rated each of the measured gastrointestinal symptom severity as described 0=No symptom, 1=Very Mild Symptom, 2= Mild Symptoms, 3= Moderate symptom, 4=Severe symptom, 5= Very Severe symptom.~PAGI-SYM is a brief (20-items with 6 sub scales) symptom severity questionnaire that captures information on common upper gastrointestinal symptoms which include including Heartburn/regurgitation, Nausea/vomiting, Fullness/early satiety, bloating, Upper abdominal pain, and Lower abdominal pain. The presented data is an average of each sub scale." (NCT03012594)
Timeframe: 3 months
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Heartburn/regurgitation | Nausea/vomiting | Fullness/early satiety | Bloating | Upper abdominal pain | Lower abdominal pain | |
| Lanreotide | 1.48 | 1.00 | 2.36 | 2.43 | 2.14 | 2.00 |
If the small bowel transit time, as measured by wireless capsule endoscopy, is decreased to < 6hrs, then patient would be considered a responder and that lanreotide is efficacious. (NCT03012594)
Timeframe: 3 months
| Intervention | minutes (Mean) | ||||
|---|---|---|---|---|---|
| Gastric emptying time | Small bowel transit time | Colonic transit time | Small bowel and Colonic transit time | Whole gut transit time | |
| Lanreotide | 371.52 | 392 | 4767 | 5159 | 5530 |
21 reviews available for lansoprazole and Esophagitis, Reflux
| Article | Year |
|---|---|
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; | 2017 |
Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Chemistry, Pharmaceutical; Clinical Trials, Phase | 2008 |
Dexlansoprazole MR.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Anti-Ulcer Agents; Delayed-Action Preparatio | 2009 |
Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Duodenal | 2013 |
[Reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Esophagitis, Peptic; Gastritis, Atrophic; | 2002 |
A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Enzyme Inh | 2003 |
Proton pump inhibitors in children: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Drug Interactions; Esophagitis, P | 2003 |
Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Famotidine; Gastroesophageal Reflux; H | 2005 |
[The clinical strategy for the Barrett's esophagus].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Ba | 2005 |
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Esomeprazole; | 2006 |
[Proton pump blockers and their significance in gastroenterology].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas | 1995 |
[Lansoprazol].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Duo | 1995 |
[Lansoprazole--profile of a new proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug A | 1994 |
Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Esophagitis, | 1993 |
Lansoprazole and omeprazole in the treatment of acid peptic disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Drug Interacti | 1996 |
Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Lans | 1997 |
[Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Cost-Benefit Analysis; Enzyme Inhibitors; Esophag | 2000 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis, | 2001 |
[Cause and prevention of nocturnal gastric acid breakthrough].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rh | 2002 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; | 1992 |
54 trials available for lansoprazole and Esophagitis, Reflux
| Article | Year |
|---|---|
Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Topics: Adult; Aged; Double-Blind Method; Drug Administration Schedule; Esophagitis, Peptic; Female; Humans; | 2020 |
Use of proton pump inhibitors to treat persistent throat symptoms: multicentre, double blind, randomised, placebo controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Esophagitis, Peptic; Female; Gastroesophageal R | 2021 |
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Topics: Adult; Aged; Biopsy; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Esophagus; Female; Gas | 2018 |
Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia.
Topics: Adult; Aged; Dyspepsia; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Heartburn; Humans; Jap | 2014 |
Management of reflux esophagitis: does the choice of proton pump inhibitor matter?
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combinati | 2015 |
Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease.
Topics: Acetamides; Adult; Aged; Aged, 80 and over; Esophagitis, Peptic; Female; Gastroesophageal Reflux; He | 2016 |
The demographic characteristics and health-related quality of life in a large cohort of reflux esophagitis patients in Japan with reference to the effect of lansoprazole: the REQUEST study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Anti-Ulcer Agents; Esophagitis, P | 2008 |
Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Aged, 80 and over; Diarrhea; D | 2009 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adaptation, Psychological; Analysis of Variance; Anti-Ulcer | 2010 |
The effects of three alternative treatment strategies after 8 weeks of proton pump inhibitor therapy for GERD in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Dru | 2011 |
Clinically distinct characteristics in patients younger than 40 years old with non-cardiac chest pain.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Chest Pain; Chi-Square Distribution; En | 2012 |
On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and | 2002 |
Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 2003 |
Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Double-Blind Method; Esomeprazole; Esophagitis, Pept | 2003 |
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double | 2003 |
The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cytochrome P-450 Enzyme System; Esophagi | 2003 |
Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2003 |
Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Esomep | 2005 |
Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Child; Dose-Response Relatio | 2005 |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug | 2005 |
Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Deglutition Disorders; Endosonography; Enzyme Inhibit | 2005 |
Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Esomeprazole; Esophag | 2006 |
Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response R | 2006 |
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Dose-Re | 2005 |
Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Double-Blind Method; Esophagitis, Peptic; Foll | 1995 |
Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Cross-Over Studies | 1995 |
A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Alcohol Drinking; Anti-Ulcer Agents; | 1995 |
Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Drug Administration Sched | 1995 |
Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Double-Blind Method; Esophagitis, | 1993 |
Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Double-Blind Method; Esophagitis | 1993 |
Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Esophagitis, | 1993 |
Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Double-Blind Method; Esopha | 1996 |
Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Enzy | 1996 |
Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Enzy | 1996 |
Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Diarrhea; Double-Blind Method; Enzyme Inhibitors; Esophagit | 1996 |
Health-related quality of life of patients with acute erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Analysis of Variance; Double-Blind Method; E | 1996 |
Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Denmark; Dose-Response R | 1996 |
Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Double-Blind Method; Enzyme Inhibitors; | 1997 |
Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Double-Blind Meth | 1997 |
Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 1997 |
Lansoprazole versus omeprazole in the treatment of reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Female; Humans; Lan | 1997 |
A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Esophagitis, Peptic | 1998 |
Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Esophagitis, Peptic; Female; Human | 1998 |
Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind | 1998 |
Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Endoscopy; Eructati | 1999 |
Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Double-Blind Method; Endosonograph | 2000 |
[Long-term maintenance treatment of reflux esophagitis resistant to H2-RA with PPI (lansoprazole)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Drug Resistance; En | 2000 |
Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Double-Blind Method; | 2000 |
Pantoprazole versus lansoprazole in French patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2001 |
[Complementary observational study of the efficacy, tolerance and safety of lansoprazole 15 mg as maintenance therapy of reflux esophagitis in daily medical practice in Belgium (record RU49749/R002].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Child; Enzyme I | 2001 |
Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 2002 |
A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre t
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Enz | 2002 |
Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Dose-Response Relationship, Drug; Double-Blind Metho | 2002 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; | 1992 |
34 other studies available for lansoprazole and Esophagitis, Reflux
| Article | Year |
|---|---|
Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China.
Topics: Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Esophagitis, Peptic; Genotype; Humans; Lansoprazole | 2022 |
An elderly woman with progressive odynophagia, epigastralgia and nausea.
Topics: Abdominal Pain; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Endoscopy, Digesti | 2018 |
Case of anaphylaxis to lansoprazole confirmed by histamine release test and oral provocation test.
Topics: Drug Hypersensitivity; Esophagitis, Peptic; Histamine; Histamine Release; Humans; Immunologic Tests; | 2019 |
The adjuvant use of lansoprazole, clonazepam and dimenhydrinate for treating intractable hiccups in a patient with gastritis and reflux esophagitis complicated with myocardial infarction: a case report.
Topics: Aged; Clonazepam; Dimenhydrinate; Esophagitis, Peptic; Gastritis; Hiccup; Humans; Lansoprazole; Male | 2013 |
High rate of clinical and endoscopic relapse after healing of erosive peptic esophagitis in children and adolescents.
Topics: Adolescent; Anti-Ulcer Agents; Body Mass Index; Child; Child, Preschool; Endoscopy; Esophagitis; Eso | 2014 |
Dexlansoprazole (Kapidex) for GERD and erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Delayed-Action Preparations; Dexl | 2009 |
The impact of lifestyle modification on the health-related quality of life of patients with reflux esophagitis receiving treatment with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Behavior Therapy; Cohort Studies; Combined Mod | 2009 |
Characteristics affecting health-related quality of life (HRQOL) in Japanese patients with reflux oesophagitis and the effect of lansoprazole on HRQOL.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Anti-Ulcer Agents; Esophagitis, P | 2009 |
Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetic Acid; Animals; Biomarkers; Cisapride; Disease Models | 2011 |
Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Esomeprazole; E | 2011 |
[Eradication of helicobacter pylori: symptomatic treatment of reflux disease?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Ther | 2002 |
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Humans; Lansoprazol | 2005 |
[Role of esophageal motility abnormalities in severe reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esophageal Moti | 2005 |
"Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cost-Benefit Analysis; Decision Support | 2005 |
Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Anorexia; Anti-Ulcer Agents; Ch | 2006 |
Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cost Sav | 2007 |
[A case of gastroesophageal reflux disease with marked eosinophilia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Eosinophilia; Esophagitis, Peptic; Female; Gastroesop | 2007 |
Lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Cos | 1995 |
[Proton pump inhibitors in the treatment of reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Humans; Lansoprazol | 1994 |
[What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Carcinogenicity Tests; Carcinoi | 1994 |
Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cost-Benefit Analysis; Esophagitis, Pept | 1997 |
Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Case-Control Studies; Cost-Benefit Analy | 1997 |
Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cell Division; Epithelial C | 1997 |
PPIs vs H2RAs for erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Cost-Benefit Analysis; Enzyme Inhibitors; Es | 1998 |
Sample size calculation in economic evaluations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angioplasty, Balloon, Coronary; Anti-Ulcer Agents; Cost-Ben | 1998 |
[Proton pump inhibitor for ulcer therapy. Tolerance profile of lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anti- | 1998 |
Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Chromatography, | 1999 |
Establishment of surgically induced chronic acid reflux esophagitis in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Disease Models, Animal; Enzyme | 1999 |
[Observations regarding internet-based applications in gastroenterology specialty practices--aspects of quality control].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Computer Liter | 2000 |
Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Decision Support Tec | 2001 |
[Administration of proton pump inhibitor caused esophageal stenosis in two patients with severe reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Drug Administration Schedule; Esophageal Stenosis; Es | 2001 |
Clinical and ethical concerns about switching patient treatment to "therapeutically interchangeable" medications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Critical Pathways; Esophagitis, Peptic; Ethics, Medical; He | 2001 |
[Clinical effect of proton pump inhibitors on reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Esophagitis, Peptic; Esophagosco | 1992 |
Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Esoph | 1991 |